T1	Participants 101 157	women with ErbB2 overexpressing metastatic breast cancer
T2	Participants 232 400	patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who have progressed on prior trastuzumab in the metastatic setting
T3	Participants 454 457	MBC
T4	Participants 569 597	women with HER2-positive MBC
T5	Participants 648 675	eligible patients (N = 112)
T6	Participants 1850 1887	patients with HER2-overexpressing MBC
